Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Surgeon Characteristics and Dialysis Vascular Access Outcomes in the United States: A Retrospective Cohort Study.

Shahinian VB, Zhang X, Tilea AM, He K, Schaubel DE, Wu W, Pisoni R, Robinson B, Saran R, Woodside KJ.

Am J Kidney Dis. 2019 Oct 1. pii: S0272-6386(19)30911-4. doi: 10.1053/j.ajkd.2019.08.001. [Epub ahead of print]

PMID:
31585684
2.

Practice-Level Adoption of Conservative Management for Prostate Cancer.

Modi PK, Kaufman SR, Herrel LA, Dupree JM, Luckenbaugh AN, Skolarus TA, Hollenbeck BK, Shahinian VB.

J Oncol Pract. 2019 Oct;15(10):e863-e869. doi: 10.1200/JOP.19.00088. Epub 2019 Sep 11.

PMID:
31509481
3.

Trends in Bariatric Surgery Procedures among Patients with ESKD in the United States.

Sheetz KH, Woodside KJ, Shahinian VB, Dimick JB, Montgomery JR, Waits SA.

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1193-1199. doi: 10.2215/CJN.01480219. Epub 2019 Jul 25.

PMID:
31345840
4.

Urologist Practice Structure and Spending for Prostate Cancer Care.

Modi PK, Herrel LA, Kaufman SR, Yan P, Borza T, Skolarus TA, Schroeck FR, Hollenbeck BK, Shahinian VB.

Urology. 2019 Aug;130:65-71. doi: 10.1016/j.urology.2019.03.029. Epub 2019 Apr 25.

PMID:
31029672
5.

Impact of Medicare Office Visit Payment Reform on Urologic Practices.

Modi PK, Kaufman SR, Caram MV, Ellimoottil C, Shahinian VB, Hollenbeck BK.

Urology. 2019 Apr;126:83-88. doi: 10.1016/j.urology.2019.01.013. Epub 2019 Jan 22.

PMID:
30682462
6.

Medicare Accountable Care Organizations and Use of Potentially Low-Value Procedures.

Modi PK, Kaufman SR, Borza T, Oliphant BW, Ryan AM, Miller DC, Shahinian VB, Ellimoottil C, Hollenbeck BK.

Surg Innov. 2019 Apr;26(2):227-233. doi: 10.1177/1553350618816594. Epub 2018 Nov 30.

PMID:
30497340
7.

National Trends in Active Surveillance for Prostate Cancer: Validation of Medicare Claims-based Algorithms.

Modi PK, Kaufman SR, Qi J, Lane BR, Cher ML, Miller DC, Hollenbeck BK, Shahinian VB, Dupree JM.

Urology. 2018 Oct;120:96-102. doi: 10.1016/j.urology.2018.06.037. Epub 2018 Jul 7.

8.

Variation in prostate cancer treatment and spending among Medicare shared savings program accountable care organizations.

Modi PK, Kaufman SR, Borza T, Yan P, Miller DC, Skolarus TA, Hollingsworth JM, Norton EC, Shahinian VB, Hollenbeck BK.

Cancer. 2018 Aug;124(16):3364-3371. doi: 10.1002/cncr.31573. Epub 2018 Jun 15.

9.

Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.

Luckenbaugh AN, Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Skolarus TA, Norton EC, Schroeck FR, Jacobs BL, Miller DC, Hollingsworth JM, Shahinian VB, Borza T.

Urology. 2018 Jun;116:68-75. doi: 10.1016/j.urology.2018.01.056. Epub 2018 Apr 6.

10.

Association Between Hospital Participation in Medicare Shared Savings Program Accountable Care Organizations and Readmission Following Major Surgery.

Borza T, Oerline MK, Skolarus TA, Norton EC, Dimick JB, Jacobs BL, Herrel LA, Ellimoottil C, Hollingsworth JM, Ryan AM, Miller DC, Shahinian VB, Hollenbeck BK.

Ann Surg. 2019 May;269(5):873-878. doi: 10.1097/SLA.0000000000002737.

PMID:
29557880
11.

Accountable care organizations and prostate cancer care.

Hollenbeck BK, Kaufman SR, Borza T, Yan P, Herrel LA, Miller DC, Luckenbaugh AN, Skolarus TA, Shahinian VB.

Urol Pract. 2017 Nov;4(6):454-461. doi: 10.1016/j.urpr.2016.11.001. Epub 2016 Nov 10.

12.

Association of the Hospital Readmissions Reduction Program With Surgical Readmissions.

Borza T, Oreline MK, Skolarus TA, Norton EC, Ryan AM, Ellimoottil C, Dimick JB, Shahinian VB, Hollenbeck BK.

JAMA Surg. 2018 Mar 1;153(3):243-250. doi: 10.1001/jamasurg.2017.4585. No abstract available.

13.

The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.

Kirk PS, Borza T, Shahinian VB, Caram MEV, Makarov DV, Shelton JB, Leppert JT, Blake RM, Davis JA, Hollenbeck BK, Sales A, Skolarus TA.

BJU Int. 2018 Apr;121(4):558-564. doi: 10.1111/bju.14075. Epub 2017 Nov 28.

14.

Early effect of Medicare Shared Savings Program accountable care organization participation on prostate cancer care.

Borza T, Kaufman SR, Yan P, Herrel LA, Luckenbaugh AN, Miller DC, Skolarus TA, Jacobs BL, Hollingsworth JM, Norton EC, Shahinian VB, Hollenbeck BK.

Cancer. 2018 Feb 1;124(3):563-570. doi: 10.1002/cncr.31081. Epub 2017 Oct 20.

15.

Urologist Practice Affiliation and Intensity-modulated Radiation Therapy for Prostate Cancer in the Elderly.

Hollenbeck BK, Kaufman SR, Yan P, Herrel LA, Borza T, Schroeck FR, Jacobs BL, Skolarus TA, Shahinian VB.

Eur Urol. 2018 Apr;73(4):491-498. doi: 10.1016/j.eururo.2017.08.001. Epub 2017 Aug 18.

16.

Reimbursement and use of intensity-modulated radiation therapy for prostate cancer.

Shahinian VB, Kaufman SR, Yan P, Herrel LA, Borza T, Hollenbeck BK.

Medicine (Baltimore). 2017 Jun;96(25):e6929. doi: 10.1097/MD.0000000000006929.

17.

Considering renal risk while managing cancer.

Shahinian VB, Bahl A, Niepel D, Lorusso V.

Cancer Manag Res. 2017 May 16;9:167-178. doi: 10.2147/CMAR.S125864. eCollection 2017. Review.

18.

Colon Cancer Screening among Patients Receiving Dialysis in the United States: Are We Choosing Wisely?

Carlos CA, McCulloch CE, Hsu CY, Grimes B, Pavkov ME, Burrows NR, Shahinian VB, Saran R, Powe NR, Johansen KL; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team.

J Am Soc Nephrol. 2017 Aug;28(8):2521-2528. doi: 10.1681/ASN.2016091019. Epub 2017 Mar 23.

19.

Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men.

Borza T, Kaufman SR, Shahinian VB, Yan P, Miller DC, Skolarus TA, Hollenbeck BK.

Health Aff (Millwood). 2017 Jan 1;36(1):108-115. doi: 10.1377/hlthaff.2016.0739.

PMID:
28069853
20.

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries.

Liede A, Hallett DC, Hope K, Graham A, Arellano J, Shahinian VB.

ESMO Open. 2016 Mar 18;1(2):e000040. eCollection 2016.

21.

Health Care Integration and Quality among Men with Prostate Cancer.

Herrel LA, Kaufman SR, Yan P, Miller DC, Schroeck FR, Skolarus TA, Shahinian VB, Hollenbeck BK.

J Urol. 2017 Jan;197(1):55-60. doi: 10.1016/j.juro.2016.07.040. Epub 2016 Jul 15.

22.

Implications of evolving delivery system reforms for prostate cancer care.

Hollenbeck BK, Bierlein MJ, Kaufman SR, Herrel L, Skolarus TA, Miller DC, Shahinian VB.

Am J Manag Care. 2016 Sep;22(9):569-75.

23.

Acute Kidney Injury Recovery Pattern and Subsequent Risk of CKD: An Analysis of Veterans Health Administration Data.

Heung M, Steffick DE, Zivin K, Gillespie BW, Banerjee T, Hsu CY, Powe NR, Pavkov ME, Williams DE, Saran R, Shahinian VB; Centers for Disease Control and Prevention CKD Surveillance Team.

Am J Kidney Dis. 2016 May;67(5):742-52. doi: 10.1053/j.ajkd.2015.10.019. Epub 2015 Dec 12.

PMID:
26690912
24.

Exploring Potential Reasons for the Temporal Trend in Dialysis-Requiring AKI in the United States.

Hsu RK, McCulloch CE, Heung M, Saran R, Shahinian VB, Pavkov ME, Burrows NR, Powe NR, Hsu CY; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team.

Clin J Am Soc Nephrol. 2016 Jan 7;11(1):14-20. doi: 10.2215/CJN.04520415. Epub 2015 Dec 18.

25.

Nephrology care prior to end-stage renal disease and outcomes among new ESRD patients in the USA.

Gillespie BW, Morgenstern H, Hedgeman E, Tilea A, Scholz N, Shearon T, Burrows NR, Shahinian VB, Yee J, Plantinga L, Powe NR, McClellan W, Robinson B, Williams DE, Saran R.

Clin Kidney J. 2015 Dec;8(6):772-80. doi: 10.1093/ckj/sfv103. Epub 2015 Nov 3.

26.

Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer.

Baillargeon J, Kuo YF, Fang X, Shahinian VB.

J Urol. 2015 Dec;194(6):1612-6. doi: 10.1016/j.juro.2015.05.099. Epub 2015 Jun 9.

PMID:
26066403
27.

Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.

Shahinian VB, Kuo YF.

BMC Urol. 2015 Apr 3;15:25. doi: 10.1186/s12894-015-0020-y.

28.

Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States.

Arellano J, Hernandez RK, Wade SW, Chen K, Pirolli M, Quach D, Quigley J, Liede A, Shahinian VB.

Cancer Med. 2015 May;4(5):713-20. doi: 10.1002/cam4.403. Epub 2015 Feb 8.

29.

Androgen-deprivation-associated bone disease.

Skolarus TA, Caram MV, Shahinian VB.

Curr Opin Urol. 2014 Nov;24(6):601-7. doi: 10.1097/MOU.0000000000000101. Review.

PMID:
25144145
30.

Effect of food insecurity on chronic kidney disease in lower-income Americans.

Crews DC, Kuczmarski MF, Grubbs V, Hedgeman E, Shahinian VB, Evans MK, Zonderman AB, Burrows NR, Williams DE, Saran R, Powe NR; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team.

Am J Nephrol. 2014;39(1):27-35. doi: 10.1159/000357595. Epub 2014 Jan 8.

31.

Regional variation in quality of prostate cancer care.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Hollingsworth JM, Shahinian VB, Hollenbeck BK.

J Urol. 2014 Apr;191(4):957-62. doi: 10.1016/j.juro.2013.10.066. Epub 2013 Oct 19.

32.

Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

Shahinian VB, Kuo YF.

J Gen Intern Med. 2013 Nov;28(11):1440-6. doi: 10.1007/s11606-013-2477-2. Epub 2013 May 14.

33.

Technology diffusion and diagnostic testing for prostate cancer.

Schroeck FR, Kaufman SR, Jacobs BL, Skolarus TA, Miller DC, Weizer AZ, Montgomery JS, Wei JT, Shahinian VB, Hollenbeck BK.

J Urol. 2013 Nov;190(5):1715-20. doi: 10.1016/j.juro.2013.05.007. Epub 2013 May 10.

34.

Estimating prevalence of CKD stages 3-5 using health system data.

Shahinian VB, Hedgeman E, Gillespie BW, Young EW, Robinson B, Hsu CY, Plantinga LC, Burrows NR, Eggers P, Saydah S, Powe NR, Saran R; CDC CKD Surveillance System.

Am J Kidney Dis. 2013 Jun;61(6):930-8. doi: 10.1053/j.ajkd.2013.01.018. Epub 2013 Mar 13.

35.

Prostate cancer: towards appropriate use of androgen deprivation therapy.

Shahinian VB.

Nat Rev Urol. 2013 Apr;10(4):192-3. doi: 10.1038/nrurol.2013.27. Epub 2013 Feb 19. No abstract available.

PMID:
23419490
36.

Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer.

Kuo YF, Montie JE, Shahinian VB.

Med Care. 2012 May;50(5):374-80. doi: 10.1097/MLR.0b013e318245a086.

37.

High-risk prostate cancer: is androgen deprivation monotherapy still appropriate?

Shahinian VB.

Asian J Androl. 2012 May;14(3):419-20. doi: 10.1038/aja.2011.182. Epub 2012 Feb 6. No abstract available.

38.

Androgen deprivation for prostate cancer: the case for "first, do no harm".

Shahinian VB.

Cancer. 2012 Jul 1;118(13):3232-5. doi: 10.1002/cncr.26624. No abstract available.

39.

Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy.

Shahinian VB.

Nat Rev Urol. 2011 Jan;8(1):9-10. doi: 10.1038/nrurol.2010.210. Epub 2010 Dec 7. No abstract available.

PMID:
21135877
40.

Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419. Epub 2010 Nov 10.

41.

Reimbursement policy and androgen-deprivation therapy for prostate cancer.

Shahinian VB, Kuo YF, Gilbert SM.

N Engl J Med. 2010 Nov 4;363(19):1822-32. doi: 10.1056/NEJMsa0910784.

42.

Association of CKD with disability in the United States.

Plantinga LC, Johansen K, Crews DC, Shahinian VB, Robinson BM, Saran R, Burrows NR, Williams DE, Powe NR; CDC CKD Surveillance Team.

Am J Kidney Dis. 2011 Feb;57(2):212-27. doi: 10.1053/j.ajkd.2010.08.016. Epub 2010 Oct 30.

43.

The role of primary care in the management of the chronic kidney disease population.

Shahinian VB, Saran R.

Adv Chronic Kidney Dis. 2010 May;17(3):246-53. doi: 10.1053/j.ackd.2010.02.003. Review.

PMID:
20439093
44.

Rhythmic changes in colonic motility are regulated by period genes.

Hoogerwerf WA, Shahinian VB, Cornélissen G, Halberg F, Bostwick J, Timm J, Bartell PA, Cassone VM.

Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G143-50. doi: 10.1152/ajpgi.00402.2009. Epub 2009 Nov 19.

45.

Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.

Gilbert SM, Kuo YF, Shahinian VB.

Urol Oncol. 2011 Nov-Dec;29(6):647-53. doi: 10.1016/j.urolonc.2009.09.004. Epub 2009 Nov 19.

46.

Cause of death in older men after the diagnosis of prostate cancer.

Ketchandji M, Kuo YF, Shahinian VB, Goodwin JS.

J Am Geriatr Soc. 2009 Jan;57(1):24-30. doi: 10.1111/j.1532-5415.2008.02091.x. Epub 2008 Nov 18.

47.

Transcriptional profiling of mRNA expression in the mouse distal colon.

Hoogerwerf WA, Sinha M, Conesa A, Luxon BA, Shahinian VB, Cornélissen G, Halberg F, Bostwick J, Timm J, Cassone VM.

Gastroenterology. 2008 Dec;135(6):2019-29. doi: 10.1053/j.gastro.2008.08.048. Epub 2008 Sep 3.

48.

Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.

Kuo YF, Goodwin JS, Shahinian VB.

BMC Health Serv Res. 2008 Jul 14;8:146. doi: 10.1186/1472-6963-8-146.

49.

Are chronic dialysis patients at increased risk for cancer?

Mandayam S, Shahinian VB.

J Nephrol. 2008 Mar-Apr;21(2):166-74. Review.

PMID:
18446710
50.

Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.

Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS.

J Clin Oncol. 2007 Dec 1;25(34):5359-65.

Supplemental Content

Loading ...
Support Center